Assessment of TB47 as a potential novel therapeutic agent: in vitro and in vivo efficacy against Mycobacterium leprae
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00318-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Gabriel Henrique Fioroni Furlan und 13 weiteren Autor:innen. Beteiligte Einrichtung: São Paulo State University (UNESP), Medical School, São Paulo, Brazil. Hauptthemen laut MEDLINE: Mycobacterium leprae, Leprostatic Agents, Leprosy. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Conselho Nacional de Desenvolvimento Científico e Tecnológico, National Key Research and Development Program of China.
Abstract (Originalsprache)
Leprosy is a chronic infectious disease caused by Mycobacterium leprae and Mycobacterium lepromatosis . The treatment typically involves multidrug therapy comprising dapsone, clofazimine, and rifampicin for 6–12 months. TB47 is a new inhibitor of the mycobacterial electron transport chain (ETC), disrupting ATP production in bacteria. This study investigated the in vitro and in vivo antimicrobial effects of TB47 on M. leprae. In vitro assays employed IDE8 tick cells infected with M. leprae , showing that after 30 days of infection, 5 ng/mL of TB47 treatment significantly impaired bacillary growth. For in vivo assays, BALB/c mice were infected with M. leprae and subjected to different treatments with varying doses of TB47 combined or not with clofazimine. Treatments were administered weekly for 90 days (13 times). The effects were assessed immediately after treatment, as well as at 120 and 210 days post-treatment. Results showed that 100 and 10 mg/kg of TB47 combined with 5 mg/kg clofazimine exhibited a bactericidal effect on M. leprae in all time points evaluated, in contrast with clofazimine monotherapy, for which the bactericidal effect was observed only 210 days post-treatment. TB47 monotherapy had a bacteriostatic effect immediately after treatment, but replication resumed at later evaluation points. Histopathological evaluation supported these findings. Combining dose-dependent TB47 with clofazimine showed an additive bacteriostatic and bactericidal effect on M. leprae , suggesting an advantageous pharmacokinetic and pharmacodynamic profile. Further research into mycobacterial ETC inhibitors could significantly impact leprosy management by providing more effective and shorter treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- São Paulo State University (UNESP), Medical School, São Paulo, Brazil.
- Lauro de Souza Lima Institute, Bauru, São Paulo, Brazil.
- Oswaldo Cruz Institute, Fiocruz, Rio de Janeiro, State of Rio de Janeiro, Brazil.
- Institute of Drug Discovery, State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
- Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
- China-New Zealand Joint Laboratory on Biomedicine and Health, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
ORCID-Profile: Gabriel Henrique Fioroni Furlan, Tianyu Zhang, Flavio Alves Lara, Ana Carla Pereira Latini
Förderung
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- National Key Research and Development Program of China
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Furlan, G. H. F., Oliveira, D. A. S., Bertoluci, D. F. D. F., Gomes, T. A., Perico, J., Martins, B. L., Do Nascimento, D. C., Diorio, S. M., Soares, C. T., Wang, S., Zhang, T., Rosa, P. S., Lara, F. A., & Pereira Latini, A. C. (2025). Assessment of TB47 as a potential novel therapeutic agent: in vitro and in vivo efficacy against Mycobacterium leprae. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00318-25
Vancouver
Furlan GHF, Oliveira DAS, Bertoluci DFDF, Gomes TA, Perico J, Martins BL, et al. Assessment of TB47 as a potential novel therapeutic agent: in vitro and in vivo efficacy against Mycobacterium leprae. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00318-25
BibTeX
@article{Furlan2025,
author = {Furlan, Gabriel Henrique Fioroni and Oliveira, Diego Augusto Souza and Bertoluci, Daniele Ferreira De Faria and Gomes, Tiago Araujo and Perico, Jonatas and Martins, Bruna Leticia and Do Nascimento, Dejair Caetano and Diorio, Suzana Madeira and Soares, Cleverson Teixeira and Wang, Shuai and Zhang, Tianyu and Rosa, Patricia Sammarco and Lara, Flavio Alves and Pereira Latini, Ana Carla},
title = {Assessment of TB47 as a potential novel therapeutic agent: in vitro and in vivo efficacy against Mycobacterium leprae},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00318-25}
}
EUVIMED